Fig 2: The PTPRA gene is highly expressed in breast cancer. (A) Relative expression level of PTPRA in 1,085 breast cancer tissues and 291 normal tissues from The Cancer Genome Atlas database. (B) Kaplan-Meier survival curves of BRCA patients with low-PTPTA and high-PTPRA in GEPIA. The blue dotted line presents patients with low PTPRA and the red dotted line represents patients with high PTPRA. PTPRA, protein tyrosine phosphatase receptor type A; HR, hazard ratio; T, tumor; N, normal; num, number; TPM, Transcripts Per Million.

Fig 3: PTPRA overexpression promotes proliferation, colony formation and migration in breast cancer cells. (A) MCF-7 cells were successfully transfected with FLAG-PTPRA vector. Western blotting was performed to evaluate exogenous PTPRA expression in wild-type and PTPRA-overexpressed MCF-7 cells with FLAG antibodies. (B) A clonogenic formation assay was performed to determine the effect of PTPRA overexpression in MCF-7 cells. Representative images are displayed. (C) Cell proliferation was assessed using a Cell Counting Kit-8 assay in control and PTPRA-overexpressing MCF-7 cells. (D) PTPRA overexpression enhanced migration in breast cancer cells compared with the empty vector group. *P<0.05 vs. respective Ctrl. PTPRA, protein tyrosine phosphatase receptor type A; Ctrl, control; OD, optical density.

Fig 4: PTPRA deficiency inhibited colony formation and migration in breast cancer cells. (A) Expression of recombinant wild-type PTPRA and PTPRA knockout in MCF-7 cells was measured by western blotting. (B) Colony formation assay was performed to determine the effect of PTPRA knockdown in MCF-7 cells. (C) Cell proliferation of PTPRA+/+ and PTPRA-/- MCF-7 cells. (D) PTPRA deficiency suppressed migratory capacity in breast cancer cells compared with wild-type MCF-7 cells. PTPRA, protein tyrosine phosphatase receptor type A; OD, optical density. **P<0.01 vs. PTPRA+/+ MCF-7 cells.